Erin Crane to Humans
This is a "connection" page, showing publications Erin Crane has written about Humans.
Connection Strength
0.204
-
Crane E. Beyond Serous: Treatment Options for Rare Endometrial Cancers. Curr Treat Options Oncol. 2022 Nov; 23(11):1590-1600.
Score: 0.042
-
Crane EK, Brown J, Lehman A, Tait DL, Naumann RW. Perioperative Recovery and Narcotic Use in Laparoscopic versus Robotic Surgery for Endometrial Cancer. J Minim Invasive Gynecol. 2021 Nov; 28(11):1898-1902.
Score: 0.038
-
Duska LR, Petroni GR, Thaker PH, Crane EK, Holman LL, Armstrong DK, Romano K, Scalici J. Update on safety and feasibility of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer. Cancer. 2025 Feb 15; 131(4):e35757.
Score: 0.012
-
Brown J, Miller A, Holman LL, Backes F, Nagel C, Bender D, Miller DS, Powell MA, Westin SN, Bonebrake A, Muller CY, Secord AA, Crane E, Schorge J, Tew WP, Sood AK, Bookman MA, Aghajanian C, Gershenson DM. Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14. Gynecol Oncol. 2024 Nov; 190:283-290.
Score: 0.012
-
Costales AB, Crane EK, Chambers L, Yao M, Chau D, Naumann WR, Debernardo R, Ricci S, Rose PG, Michener CM. Laparoscopic predictability of minimally invasive interval debulking in advanced ovarian cancer: The MIID-SOC trial. Gynecol Oncol. 2024 Jun; 185:143-147.
Score: 0.012
-
Holloway RW, Thaker P, Mendivil AA, Ahmad S, Al-Niaimi AN, Barter J, Beck T, Chambers SK, Coleman RL, Crafton SM, Crane E, Ramez E, Ghamande S, Graybill W, Herzog T, Indermaur MD, John VS, Landrum L, Lim PC, Lucci JA, McHale M, Monk BJ, Moore KN, Morris R, O'Malley DM, Reid TJ, Richardson D, Rose PG, Scalici JM, Silasi DA, Tewari K, Wang EW. A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer. Int J Gynecol Cancer. 2023 Sep 04; 33(9):1458-1463.
Score: 0.011
-
Lees BF, Johnson S, Donahue E, Bose R, Brown J, Crane E, Puechl A, Tait D, Naumann RW. Improved Rates of Same-day Discharge in Patients Undergoing Surgery for Endometrial Cancer Following the COVID-19 Pandemic. J Minim Invasive Gynecol. 2022 Nov; 29(11):1248-1252.
Score: 0.010
-
Levytska K, Yu Z, Wally M, Odum S, Hsu JR, Seymour R, Brown J, Crane EK, Tait DL, Puechl AM, Lees B, Naumann RW. Enhanced recovery after surgery (ERAS) protocol is associated with lower post-operative opioid use and a reduced office burden after minimally invasive surgery. Gynecol Oncol. 2022 Sep; 166(3):471-475.
Score: 0.010
-
Brancazio SN, Lehman A, Kemp EV, Brown J, Crane EK, Tait DL, Taylor VD, Naumann RW. Factors Associated with Same Day Discharge after Laparoscopic Surgery in Gynecologic Oncology. J Minim Invasive Gynecol. 2022 Jan; 29(1):114-118.
Score: 0.010
-
Toboni MD, Crane EK, Brown J, Shushkevich A, Chiang S, Slomovitz BM, Levine DA, Dowdy SC, Klopp A, Powell MA, Thaker PH. Uterine carcinosarcomas: From pathology to practice. Gynecol Oncol. 2021 Jul; 162(1):235-241.
Score: 0.010
-
Tait DL, Lehman A, Brown J, Crane EK, Kemp EV, Taylor VD, Naumann RW. Comparison of Perioperative Outcomes between Minimally Invasive Sentinel Node Biopsy and Full Lymphadenectomy for Endometrial Cancer. J Minim Invasive Gynecol. 2021 Aug; 28(8):1514-1518.
Score: 0.009
-
Levine MD, Brown J, Crane EK, Tait DL, Naumann RW. Outcomes of Minimally Invasive versus Open Radical Hysterectomy for Early Stage Cervical Cancer Incorporating 2018 FIGO Staging. J Minim Invasive Gynecol. 2021 Apr; 28(4):824-828.
Score: 0.009
-
Lehman A, Kemp EV, Brown J, Crane EK, Tait DL, Taylor VD, Naumann RW. Pre-emptive Non-narcotic Pain Medication before Minimally Invasive Surgery in Gynecologic Oncology. J Minim Invasive Gynecol. 2021 Apr; 28(4):811-816.
Score: 0.009
-
Naumann RW, Morris JC, Tait DL, Higgins RV, Crane EK, Drury LK, Amacker-North L, Templin M, Brown J. Patients with BRCA mutations have superior outcomes after intraperitoneal chemotherapy in optimally resected high grade ovarian cancer. Gynecol Oncol. 2018 Dec; 151(3):477-480.
Score: 0.008